EGF vs TB4-Frag

Binds EGFR (EGF receptor / ErbB1), activating RAS/MAPK and PI3K/Akt signaling cascades. Promotes keratinocyte and fibroblast proliferation, accelerates wound re-epithelialization, and stimulates collagen and hyaluronic acid production.

Epidermal growth factor (EGF) is an endogenous 53-amino-acid polypeptide that binds the EGF receptor (EGFR) to stimulate cell proliferation, migration, and differentiation in epithelial and mesenchymal cells; it plays a fundamental role in wound healing, skin regeneration, and tissue repair by promoting keratinocyte and fibroblast activation through tyrosine kinase-mediated downstream signaling. EGF activates EGFR tyrosine kinase to initiate PI3K/Akt and MAPK/ERK proliferative signaling cascades; in wound contexts, topically applied recombinant EGF accelerates epithelialization and granulation tissue formation, and injectable EGF has been evaluated for wound bed preparation in diabetic and chronic wounds. Clinical trials of recombinant human EGF for wound healing — including a PubMed-indexed human clinical trial in diabetic foot ulcers — have demonstrated improvements in wound closure and tissue regeneration; recombinant EGF preparations are approved in some countries (Cuba, South Korea) for diabetic wound healing under prescription conditions. Topically applied EGF has no FDA approval in the United States for wound healing or cosmetic applications; recombinant EGF-based wound therapeutics are available internationally under national regulatory approvals outside the US, and EGF is widely incorporated into cosmetic formulations at concentrations where receptor activation and clinical benefit have not been independently validated.

Active fragment of Thymosin Beta-4; promotes actin dynamics and cell migration; activates hair follicle stem cells; modulates inflammatory signaling

TB-4 Fragment (Thymosin Beta-4 17-23) is a short synthetic peptide derived from the thymosin beta-4 protein, investigated for wound healing, skin repair, and hair follicle regeneration. Thymosin beta-4 facilitates actin sequestration, keratinocyte migration, and stem cell recruitment to sites of tissue injury; the 17-23 fragment retains portions of these bioactive properties. Peer-reviewed studies demonstrate that thymosin beta-4 promotes hair follicle stem cell activation and dermal tissue regeneration in preclinical models, providing a mechanistic basis for skin-related applications. TB-4 Fragment is an investigational peptide with limited human clinical data and is not approved by the FDA for any therapeutic use. TB4-Frag vs full-length thymosin beta-4 TB-4 Fragment (residues 17–23 of thymosin beta-4, sequence: Leu-Lys-Lys-Thr-Glu-Thr-Gln) is a distinct, smaller molecule compared to full-length thymosin beta-4 (43 amino acids). The fragment retains the actin-binding motif that drives keratinocyte migration and stem cell recruitment — mechanisms central to the wound healing and hair follicle regeneration research attributed to TB4 — but lacks the full protein's Ac-SDKP-generating and anti-fibrotic properties. The lower molecular weight of the fragment (approximately 870 Da vs ~4,900 Da for full Tb4) is proposed to improve transdermal penetration for topical applications, making TB4-Frag relevant to cosmetic skin and scalp formulations where injectable administration is not used. In the research peptide market, TB4-Frag is positioned as a topical active for skin repair and hair density contexts; full-length thymosin beta-4 (sold as TB-500) is used for systemic/injectable recovery and tissue repair applications. The two should not be conflated — they have different sequences, molecular weights, and proposed application contexts despite sharing a mechanistic origin.